Work

A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response

Year: 2012

Type: article

Study design: Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1097/jto.0b013e3182435aa6

Authors: Ramesh Rengan, Rosemarie Mick, Daniel Pryma, Mark A. Rosen, Lilie L. Lin, Amit M. Maity, Tracey L. Evans, James P. Stevenson, Corey J. Langer, John Kucharczuk, Joseph Friedberg, Susan Prendergast, Tiffany Sharkoski, Stephen M. Hahn

Institutions: University of Pennsylvania, University of Pennsylvania Health System

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Eli Lilly and Company, GlaxoSmithKline, National Institutes of Health, Genentech, National Cancer Institute

Award: DCE-MRI for Assessment of Vascular Normalization by Nelfinavir in Lung Cancer

OpenAlex ID: W2079046174

FWCI: 7.591

Cites: 28

Cited by: 75

Related to: 10